Tag: the war on (some) drugs

17 Drugs Most Potentially Toxic to the Liver Identified: UPenn Study

Researchers identified 17 most potentially liver-toxic drugs in a Monday study published in JAMA Internal Medicine.

The study authors said they ranked the drugs according to the rates of severe liver injury, though they could not determine if the 17 drugs caused the acute injury in every event.

According to their findings, 11 of the 17 drugs identified may have wrongly received a lower hepatotoxicity (potential to harm the liver) rank according to the current ranking system.

To establish drugs’ potential for liver toxicity, researchers have used case reports of liver toxicity listed on the National Institutes of Health LiverTox website. Case reports are detailed reports on an individual patient; they often describe a novel or unusual patient case. Doctors write case reports when encountering a unique or novel patient presentation in their clinics. Some doctors write case reports, and others do not.

This “undoubtedly leads to underreporting,” senior author Dr. Vincent Lo Re, III, associate professor of medicine and epidemiology at the University of Pennsylvania, told The Epoch Times.

Because the drug rankings are based on voluntary clinician reporting instead of large population studies, the toxicity profile of some drugs may be missed if the clinician does not publish a case report.

Keep reading

Woman spent a MONTH in jail because police mistook dried SpaghettiO’s residue on a spoon for meth before crime lab tests finally realized their error

A Florida woman is free to eat pasta in her car once again after serving a month in jail because cops confused a crusty spoon in her possession with SpaghettiO’s residue as being the drug methamphetamine.

  • Ashley Gabrielle Huff, 23, was arrested on July 2 by police after they suspected her of having meth residue on a spoon that was actually sauce
  • Huff served one month in jail because she could not make court dates or pay bond and even considered admitting to a crime she did not commit
  •  The Crime Lab report showed no controlled substances on the spoon submitted for testing,’ said Judicial Circuit District Attorney Lee Darragh

Ashley Gabrielle Huff, 23, was arrested on July 2 by the Gainesville police department after they suspected her of having meth residue on a spoon in her car that she hard pressed was SpaghettiO’s residue.

She was released from Hall County Jail on Thursday after a crime lab analysis confirmed that the spoon had sauce residue instead of drugs, reports The Gainesville Times.

Keep reading

Slow-release ketamine tablets help prevent depression relapses, UK trial finds

Slow-release ketamine pills have been found to prevent relapse into depression, in a trial that could pave the way for a new treatment option for patients with severe illness.

Ketamine is already used as a treatment for depression when conventional antidepressant drugs and therapy have failed. But ketamine is currently only administered intravenously, which requires supervision in a clinic, and the National Institute for Health and Care Excellence ruled that a ketamine-like nasal spray should not be available on the NHS.

If the apparent benefits are confirmed in a larger trial, ketamine tablets could be taken at home more cheaply, conveniently and potentially with fewer side-effects, the researchers said.

“We’re seeing a clinically meaningful effect,” said Prof Allan Young, of King’s College London and a co-author of findings. “This is not a definitive result, but the effect size is gratifyingly large.”

The phase 2 trial used an extended-release formulation of ketamine, designed to release the drug into the body over a 10-hour period. The hope was that this would make the treatment more effective and reduce adverse effects such as dissociation, high blood pressure, a racing heart or feelings of numbness. The “slow peak” would also reduce the drug’s abuse potential, Young said.

Keep reading

D.C. Subpoena Causes Zyn to Suspend Online Sales

The tobacco company Philip Morris International, which owns the nicotine-pouch brand Zyn, announced Monday that it will be ceasing online sales for North America, following a subpoena sent by the attorney general of the District of Columbia. The subpoena follows from a 2022 decision by the district to ban flavored nicotine products.

The move to target Zyn comes amid Washington’s widespread crime problem. Violent crime increased by 40 percent in 2023, and the highest homicide rate is at its highest in over two decades. Nevertheless, more than 67 percent of arrests made are declined to be prosecuted, and D.C. is currently facing its largest police shortage in half a century. 

Keep reading

Louisiana Governor Vetoes Bill That Would Have Let Him Pardon Past Marijuana Convictions

The governor of Louisiana has vetoed a bill that would have allowed him and future governors to issue pardons for people with past marijuana convictions.

Gov. Jeff Landry (R) rejected the legislation on Wednesday, about a month after it was approved in the legislature. It remains to be seen what he will do with separate proposals to decriminalize cannabis paraphernalia and regulate hemp products that have also been sent to his desk.

The pardon bill from Rep. Delisha Boyd (D) would have made people convicted of cannabis possession eligible for a gubernatorial pardon after paying all court costs associated with the offense, without the need for a recommendation from the Board of Pardons.

Individuals could have only received a pardon for their first possession offense, and anyone “who received such pardon shall not be entitled to receive another pardon by the governor pursuant to this Section,” the legislation says.

Kevin Caldwell, Southeast legislative manager for the advocacy group Marijuana Policy Project (MPP), said his organization is “saddened” by the governor’s veto of the bill.

“This legislation would have granted him the authority to pardon tens of thousands Louisianans who have a cannabis conviction on their records,” he told Marijuana Moment in an email. “This is a missed opportunity to help everyday citizens better their lives and economic opportunities.”

“This legislation was always about improving opportunities,” Caldwell added. “The strong bipartisan support this legislation achieved is a testament to the level of support sensible cannabis policy has in Louisiana.”

Meanwhile, the governor still has several other cannabis bills pending action.

Keep reading

Arizona Governor Signs Bill To Allow Workers’ Compensation For MDMA Treatment, Despite Vetoing Psilocybin Proposal

The governor of Arizona has signed a bill into law that would allow firefighters and peace officers with post-traumatic stress disorder (PTSD) to get workers’ compensation coverage for MDMA therapy if it is federally legalized.

While Gov. Katie Hobbs (D) vetoed a separate proposal to legalize psilocybin service centers this week, she gave final approval on Tuesday to legislation that would authorize the Industrial Commission of Arizona to provide public safety officials who have PTSD with compensation for a one-course treatment of MDMA if the drug is approved by the federal Food and Drug Administration (FDA).

The measure is being enacted weeks after an FDA advisory committee recommended against approving a new drug application for MDMA-assisted therapy, drawing criticism from advocates and certain lawmakers, including a GOP congressman who personally benefitted from psychedelic treatment.

The Arizona bill from Sen. David Gowan (R) is fairly limited in its scope, especially compared to the psychedelics services legislation the governor vetoed this week. Not only would it require FDA approval of MDMA, but it also doesn’t create a framework for therapeutic administration. It simply allows officials to approve workers compensation for a course of MDMA-assisted treatment sessions.

“If an independent medical examination reveals a treatment protocol of midomafetamine is deemed a reasonable and necessary treatment and follows the treatment guidelines established by the Industrial Commission of Arizona, workers’ compensation coverage may include on complete course of a treatment protocol of midomafetamine as prescribed by a psychiatrist,” the bill text says.

The commission would also be required to submit a report about the costs of the MDMA treatment to the Joint Legislative Budget Committee each year starting on or before January 1, 2026.

Keep reading

If Opiates Are Killing Americans, Why Won’t the FDA Let Us Try an Alternative?

For more than a decade, patients who’ve needed certain controlled medications have suffered from ill-advised, untenable policies the U.S. government has instituted, allegedly to mitigate the ever-surging numbers of drug overdose deaths. These policies have been a dismal failure on multiple fronts: Not only have deaths continued to surge, but the terrifying intrusion of the Drug Enforcement Administration (DEA) into the practice of medicine has had a chilling effect on patients and their physicians. 

As the DEA relentlessly tightens production quotas on medications for pain and ADHD, it has begun tracking every pill, making doctors increasingly reluctant to prescribe any controlled drugs and leaving many patients in a lurch. Perhaps worse, DEA production quotas have caused the back-order of multiple drugs—an increasingly common burden for patients, even those fortunate to have doctors willing to risk a DEA drug bust for simply doing their job.

The ill and disabled suffer the most. Virtually all patients who have diseases or chronic pain conditions will say that the emergency department is the single worst place to go for relief from severe pain. Doctors and hospitals are often more concerned about law enforcement looking over their shoulders than patient care. Patients desperate for pain relief often turn to street drugs, where they fall victim to counterfeit pills that contain fentanyl (or worse) instead of a legal opioid. 

By contrast, doctors in Australia, Canada, the United Kingdom, and throughout Europe have been using a fixed-dose, inhaled general anesthesia medicine that effectively reduces acute pain—a medication denied to Americans by a seemingly indifferent Food and Drug Administration (FDA). 

Doctors commonly used methoxyflurane (Penthrane) as a general anesthetic in the 1960s and 1970s. But, because it had toxic effects on the liver and kidneys, anesthesiologists gradually stopped using it and turned to safer anesthetics. In 2005, the FDA removed methoxyflurane from the market.

However, an Australian company, Medical Developments International, has been marketing a lower-dose, self-administered, single-use nasal inhaler version of methoxyflurane for 30 years. Its brand name is Penthrox, though many people refer to it as the “green whistle,” because of the package it comes in. People living in Europe have had access to the green whistle since 2015, and Canadian patients have had it since 2018. 

In 2020, a randomized controlled clinical trial in the U.K. demonstrated that the drug saved an average of 71 minutes in providing pain relief to accident and emergency department patients. Likewise, a 2020 Australian trial found that a methoxyflurane inhaler “was associated with clinically significant lower pain scores compared to standard therapy.” While it may cause drowsiness in some people, methoxyflurane at this low dose has few adverse effects, such as liver and kidney toxicity, and there are no reported cases of addiction or abuse. 

In 2022, the FDA finally lifted its “clinical hold” on methoxyflurane nasal inhalers and has allowed its manufacturer to resume FDA-supervised clinical trials. Unfortunately, this is an unnecessary waste of time.

Keep reading

Older Patients Using Medical Cannabis ‘Experience Considerable Improvement In Health And Well-Being,’ Study Finds

A new study on the impacts of medical marijuana on older adults finds that cannabis-based products may provide multiple therapeutic benefits for the demographic, including for health, well-being, sleep and mood.

Authors also observed “sizable reductions in pain severity and pain interference among older aged patients [reporting] chronic pain as their primary condition.”

The research, published this week in the journal Drugs and Aging, is meant to address what authors call “a general paucity of high quality research” around cannabis and older adults “and a common methodological practice of excluding those aged over 65 years from clinical trials” at a time when older patients are increasingly turning to medical marijuana for relief.

“International evidence that older individuals may be the fastest-growing increase in the use of medical marijuana, coupled with their frequent exclusion from controlled trials, indicates a growing need for real-world evidence to assess the effectiveness and safety of these drugs for older individuals,” the paper says.

Keep reading

Arizona’s Democratic Governor Vetoes Bill To Legalize Psilocybin Service Centers

The Democratic governor of Arizona has vetoed a bill to legalize psilocybin service centers where people could receive the psychedelic in a medically supervised setting.

Less than a week after lawmakers gave final approval to the legislation, Gov. Katie Hobbs (D) rejected it on Tuesday, arguing that while the psychedelic may hold therapeutic potential, “we do not yet have the evidence needed to support widespread clinical expansion.”

“Arizonans with depression and PTSD deserve access to treatments that may be seen as outside the mainstream, but they should not be the subject of experiments for unproven therapies with a lack of appropriate guardrails,” the governor said in a veto message.

She also said that the bill’s estimated cost is $400,000 per year, which wasn’t accounted for in the budget.

Under the now-vetoed legislation, the Department of Human Services (DHS) would have been authorized to license psilocybin-assisted therapy centers in the state, where trained facilitators could have administered the psychedelic.

The measure would have significantly expanded on Arizona’s existing research-focused psychedelics law that provides $5 million in annual funding to support studies into psilocybin therapy.

Hobbs cited that research funding in her statement, saying the goal is to “ensure that those who seek psilocybin treatment are doing so confidently and safely under proper supervision of qualified professionals with documented and verified research to support the treatment.”

She said that money “will be allowed to continue with this year’s budget,” with a separate funding bill she signed into law on Tuesday protecting those dollars, which are exempt from lapsing appropriations provisions.

The vetoed proposal, meanwhile, would have established an Arizona Psilocybin Advisory Board, comprised of members appointed by the governor and legislative leaders. Representatives of the attorney general’s office and DHS, as well as military veterans, first responders, scientists with experience with psilocybin and physicians would have been among the members.

The board would have been responsible for establishing training criteria for psilocybin service center staff, making recommendations on the implementation of the law, and studying the science and policy developments related to psychedelics.

Sen. T. J. Shope (R), the bill’s sponsor, told The Center Square that the veto is a “disappointing result after months of hard work and the overwhelming bipartisan support this received in both houses of the Legislature this year.”

The senator added that if lawmakers were still in session, he’d be pushing for a vote to override the veto, but he’ll have to “settle for trying again next year.”

Keep reading

Portland Baseball Team Becomes First Sports Team to Legally Sell THC Products During Games

The Portland Pickles baseball organization will become the first sports team in the United States to sell marijuana-based products during a live sporting event legally.

In an announcement, the Pickles revealed they have a new partnership with Cycling Frog, which sells THC-based seltzer drinks.

The team will start selling the THC-based seltzer drinks at their stadium on June 18th.

According to Oregon Live, the Seltzer drink contains 2MG of THC and 4MG of CBG and is available in lemon and passion fruit flavors.

Ross Campbell, the Pickles’ VP of Business Development, said, “The Portland Pickles have a responsibility in the sports industry to take leaps and set a precedent of innovative partnerships.”

Fans who want to purchase the drink must be over 21.

Keep reading